The effect of calcium channel blockers on the outcome of acute myeloid leukemia

Young Kwang Chae, Anastasios Dimou, Sherry Pierce, Hagop Kantarjian, Michael Andreeff*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The effect of calcium channel blockers (CCBs), beta blockers and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) on the prognosis of patients with acute myeloid leukemia (AML) is largely unknown. We collected data on the use of these medications in 1043 patients with AML, excluding promyelocytic leukemia, diagnosed and treated at M. D. Anderson Cancer Center between 2000 and 2012. Treatment with either amlodipine or diltiazem predicted a worse overall survival (hazard ratio [HR] 1.6, 95% confidence interval [CI] 1.22-2.06, p < 0.0001). There was no difference in survival depending on whether patients were taking beta blockers, ACE inhibitors or ARBs. The effect of CCBs on survival was independent from the National Comprehensive Cancer Network risk classification, age, performance status, response to treatment, year of diagnosis and CD34 levels, assessed by flow cytometry (HR 1.39, 95% CI 1.05-1.80, p = 0.02). Treatment with either amlodipine or diltiazem predicts worse survival in patients with AML independent of known prognostic factors.

Original languageEnglish (US)
Pages (from-to)2822-2829
Number of pages8
JournalLeukemia and Lymphoma
Volume55
Issue number12
DOIs
StatePublished - Dec 1 2014

Keywords

  • Acute myeloid leukemia
  • Amlodipine
  • Angiotensin receptor blockers
  • Angiotensin-converting enzyme inhibitors
  • Beta blockers
  • Calcium channel blockers
  • Diltiazem

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The effect of calcium channel blockers on the outcome of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this